" class="no-js "lang="en-US"> Twelve - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Twelve | Pharmtech Focus

Twelve

About Twelve

Twelve

We’re Twelve, the carbon transformation company, a new kind of chemical company built for the climate era. Our breakthrough technology eliminates emissions by turning CO2 into essential products that today are made from fossil fuels. We call it carbon transformation. We’re reinventing what it means to be a chemical company, on a mission to create a climate positive world and a fossil free future.

Related Story

Industry News

 Twelve and LanzaTech Partner to Produce the World’s First Polypropylene From CO2 | Pharmtech Focus

Twelve and LanzaTech Partner to Produce the World’s First Polypropylene From CO2

September 2 2021

Carbon transformation company Twelve and biotechnology company LanzaTech have partnered to transform CO2 emissions into polypropylene, a key polymer used […]